Reprogramming Cancer And Competing With China With Earli's Cyriac Roeding

On this week's episode of the Business of Biotech, Cyriac Roeding talks about cofounding and leading Earli, a "bioAI" company using synthetic DNA switches and cancer-binding lipid nanoparticles to transform cancer cells into immune therapy-producing factories in vivo. Cyriac also discusses China’s newest five-year plan for biotech (2026 to 2030), why U.S. funding cycles are pushing innovation offshore, and how a U.S. sovereign wealth fund could support preclinical and early-stage drug development leadership at home.

Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

Get in touch with guest and topic suggestions: ben.comer@lifescienceconnect.com

Find Ben Comer on LinkedIn https://www.linkedin.com/in/bencomer/

Find the Business of Biotech wherever you get your podcasts.